# Predictive Value of Early Changes of Chromogranin A Levels in Patients With Neuroendocrine Tumours Treated With PRRT

> **NCT06183047** · — · COMPLETED · sponsor: **Military Institute od Medicine National Research Institute** · enrollment: 38 (actual)

## Conditions studied

- Early Release of Chromogranin A (CgA)

## Interventions

- **DIAGNOSTIC_TEST:** early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).

## Key facts

- **NCT ID:** NCT06183047
- **Lead sponsor:** Military Institute od Medicine National Research Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-01
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2023-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06183047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06183047, "Predictive Value of Early Changes of Chromogranin A Levels in Patients With Neuroendocrine Tumours Treated With PRRT". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06183047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*